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Introduction:   
Calcium phosphate cements (CPCs) have been widely used as an alternative to 
biological grafts as they present excellent biocompatibility and osteoconductive 
properties.  An additional advantage is their self-setting nature, which makes 
them injectable and allows the use of a minimally invasive surgical procedure 
during clinical use.  However, CPCs do not have sufficient intrinsic porosity to 
allow tissue ingrowth and are characterized by a very slow degradation rate.  
They also have poor setting characteristics and low compressive and flexural 
strength.  Bioactive glasses (BGs) are synthetic silica-based bioactive materials 
that are biocompatible, resorbable and osteoinductive.  They have the ability to 
bond to bone by forming a biologically active bone-like apatite layer on their 
surface that acts as a template for calcium phosphate precipitation and new bone 
formation. As a result, composite bioglass/calcium phosphate cements have been 
developed.  Further in vitro studies have reported that fluoride-substituted 
hydroxyapatite augments osteoblastic activity and differentiation.  In addition, 
studies have also shown that octacalcium phosphate (OCP) is more soluble when 
compared with calcium hydroxyapatite, and that the resorption of OCP is 
followed by new bone formation. Novel work previously performed by the 
authors, has successfully introduced BG into (i) hydroxyapatite, (ii) octacalcium 
phosphate and (iii) fluorohydroxyapatite cements without compromising the 
setting time. The aim of this study was to investigate bone formation and contact 
to these three novel BG/CPC cements following implantation in an ovine 
femoral condyle critical-sized defect. Our hypothesis was that the novel cements 
would augment bone formation to equal amounts when compared with a 
commercially available calcium phosphate cement (Hydroset™). 
 
Methods:  
     Twenty-four 8 x 15 mm deep defects were created in the medial femoral 
condyles of 6 female, skeletally mature commercially cross-bred sheep. Ethical 
approval was granted and all procedures were carried out in compliance with the 
UK’s Home Office Regulations (Animal Scientific Procedures Act 1986). The 
cements investigated were BG/CPC composites, however the calcium phosphate 
component was composed of either (1) OCP/Brushite (OCP), (2) a 
fluorohydroxyapatite (FHA) or (3) hydroxyapatite (HA).  Groups 1 – 3 were 
also compared with (4) Hydroset™, a commercially available calcium phosphate 
cement.  Cements remained in vivo for 12 weeks (n=6). Fluorochrome markers 
(oxytetracycline and calcein green) were administered in order to measure bone 
apposition rates and following retrieval, specimens were processed for 
undecalcified histology.  A thin histological section was made through the centre 
of each defect and image analysis techniques were used to quantify bone 
apposition rates and bone-implant contact at 12 weeks post surgery.  The 
compressive strength (MPa) of each of the cements was tested using an 
indentation method (Zwick Proline 500) in two central positions (at least 2 mm 
apart) within the cement mantle following retrieval. Mann Whitney U tests were 
used for statistical analysis where p<0.05 was considered significant. 
 
Results:   
Bone Apposition Rates: Results are presented as mean and standard deviation.  
Results showed that greatest bone turnover rates were measured in the 
Hydroset™ group (mean, 1.191 ± 0.345 µm/day-1).  Independent non-parametric 
analysis showed that significantly increased apposition rates were measured in 
the Hydroset™ group when compared with OCP filled (mean, 0.740 ± 0.156 
µm/day-1) (p = 0.028) and FHA defects (mean, 0.839 ± 0.141 µm/day-1) (p = 
0.047).  No significant difference was found when Hydroset™ and HA samples 
were compared.   Significantly increased bone turnover rates were measured 
adjacent to the HA cement specimens (mean, 1.151 ± 0.274 µm/day-1) when 
compared with OCP samples (p = 0.028).  No other significant differences were 
found.   
Bone-Implant Contact: Extensive bone-cement contact was measured in all 
experimental groups however the greatest amount was measured in specimens in 
the OCP group (mean, 95.47 ± 3.22%).  The lowest bone-cement contact values 
were measured in HA samples (mean, 93.02 ± 2.32%).  Significantly less bone 
contact was measured in HA samples when compared with FHA samples (mean, 
94.55 ± 1.77%) (p = 0.014).  No other significant differences were found (Figure 
1).  Qualitative evaluation using light and backscattered scanning electron 
microscopy showed mature lamellar bone in contact with all cement surfaces.  In  
 
 
 
all groups and where pores were present within the cement mantle, new bone 
growth was seen growing preferentially along the cement surface.  Compressive  
Strength: Mechanical testing showed the compressive strength of cements in 
each of the groups were similar.   No significant differences were found when 
each of the groups were compared (Figure 2). 
 
  
 
 
 
Figure 3: Photomicrographs showing bone remodeling adjacent to each of the 
groups investigated following 12 weeks in vivo.  Arrows point to new bone 
formation at the bone-cement interface. 
 
Discussion  
Excellent osteointegration was seen adjacent to all cement compositions with 
new bone formation seen surrounding implants in each group.  Results from this 
study showed that the incorporation of fluoride within the hydroxyapatite lattice 
and the formation of OCP/Brushite BG/CPCs were as bioactive as the 
commercially available calcium phosphate cement Hydroset™.  These cements 
are able to be injected and their compressive strength once set, and after 12 
weeks in vivo, indicates that they may be excellent bone void fillers and may 
have potential uses for vertebroplasty applications. Further work is needed to 
assess the resorbability of the cements over time. 
 
Significance: The use of OCP and fluorohydroxyapatite bioglass cements has the 
potential to be used clinically as bone void fillers. 
 
Figure 1: %Bone-Cement Contact  
In each of the experimental groups 
 at 12 weeks. 
 
Figure 2: Compressive Strength in  
each group at 12 weeks. 
 
